Abstract:Chemokine receptor CCR2 is a member of the seven-transmembrane G-protein-coupled receptor superfamily, and is predominantly expressed on monocytes and macrophages. The interaction of the chemokine CCL2 with the CCR2 plays an important role in the recruitment of monocytes, natural killer cells, dendritic cells and T-lymphocytes. Recent studies have linked the CCL2/CCR2 axis to various inflammatory diseases such as rheumatoid arthritis, multiple sclerosis, atherosclerosis, diabetes and even cancer. Thus, small molecule antagonists which can block the binding of CCR2 and CCL2 represent new therapeutic interventions of the inflammation-related diseases. By comprehensively analyzing the structures of the literature-reported potent CCR2 antagonists, we concluded a pharmacophore model for CCR2 inhibition, including a basic amino center, a hydrophobic aromatic ring on the right-hand side, and an amide group which serves as a hydrogen bond acceptor and a hydrogen bond donor. Then we performed the lead deconstruction and pharmacophore model-based privileged fragment reassembly strategy to discover new scaffold small molecule CCR2 inhibitors. The lead-like privileged scaffolds of alpha-alkyl-gamma-aminobutanamide and glycinamide were selected to combine with novel aromatic moiety and amide portion, delivering 3 classes of new structure CCR2 inhibitors. Total 11 compounds were designed and synthesized via a facile convergent synthetic procedure. The CCR2 antagonism activity evaluation revealed that N-(3-aminocyclopentane-carboxamido) methyl) benzamide was an active scaffold (exemplified by 1a, IC50= 25 nmol/L). The preliminary structure-activity relationship study indicated that the basic amino group and the lipophilic aliphatic moiety and small size aromatic group are important for the interaction with CCR2 protein. The replacement of the basic amino group with an amide would lead to the significant loss of the activity. This work provides a promising new structure CCR2 inhibitor and useful SAR conclusions which will promote the further development of CCR2 inhibitor into drug candidate.

Molecular design for antagonisting C5a anaphyl atoxin and the activity examination of the peptide

Design, Synthesis and Functional Validation of Peptide Inhibitors Based on TRPV1 Ion Channel Agonist RhTx.

Chimeric Protein Probes for C5a Receptors Through Fusion of the Anaphylatoxin C5a Core Region with a Small-Molecule Antagonist

Identification of Conformational Core Epitope Lys(68) in C5a Based on the 3-D Modeling Complex C5a and Its Functional Antibody F20

Chemical Synthesis and Racemic Crystallization of Rat C5a-desArg

Pharmacophore Model-based Design and Synthesis of New Structure Small Molecule CCR2 Inhibitors

Functional Identification of the Stable Transfection C5ar Cell Line Molt-4

Structure-based drug design using GPCR homology modeling: toward the discovery of novel selective CysLT2 antagonists.

Structure of the complement C5a receptor bound to the extra-helical antagonist NDT9513727

Design and Synthesis of Novel Cathepsin C Inhibitors with Anti-Inflammatory Activity

Synthesis and evaluation of disulfide-rich cyclic α-conotoxin [S9A]TxID analogues as novel α3β4 nAChR antagonists

Rational Design of Peptides with Anti-Hcv/Hiv Activities and Enhanced Specificity

Structure-Based Affinity Maturation of A Chimeric Anti-Ricin Antibody C4c13

Rational Design of Potent α-Conotoxin PeIA Analogues with Non-Natural Amino Acids for the Inhibition of Human α9α10 Nicotinic Acetylcholine Receptors

A Novel Domain Antibody Rationally Designed Against TNF-α Using Variable Region of Human Heavy Chain Antibody As Scaffolds to Display Antagonistic Peptides

Medicinal chemistry, pharmacology, and therapeutic potential of α-conotoxins antagonizing the α9α10 nicotinic acetylcholine receptor

IsCT-based analogs intending better biological activity

C-Terminal Amination of a Cationic Anti-Inflammatory Peptide Improves Bioavailability and Inhibitory Activity Against LPS-Induced Inflammation

Biological and mutational analyses of CXCR4-antagonist interactions and design of new antagonistic analogs

Rational design, expression and biological activity assessment of a novel peptide based on ricin toxin antibody

Design and Synthesis of Tri‐substituted Chiral Pyrrolidin‐2‐one Derivatives As CCR4 Antagonists